SNBL

SNBL is a contract research organization (CRO) that provides comprehensive support for pharmaceutical development, primarily through non-clinical and clinical research services. The company's core offering encompasses a full spectrum of drug development processes, from discovery and preclinical studies to clinical trials. SNBL leverages its expertise in areas such as pharmacology, toxicology, and bioanalysis, along with translational research capabilities, to assist clients in advancing new therapeutic candidates through regulatory pathways.

The company was founded in September 1957 by Ryoichi Nagata. Nagata established SNBL with the insight that specialized, independent research services would be crucial for the efficient and effective development of new medicines. His vision led to the creation of one of Japan's earliest organizations dedicated to contract research, providing critical infrastructure and scientific rigor to the nascent pharmaceutical industry.

SNBL serves pharmaceutical companies and biotechnology firms globally, acting as a pivotal partner in bringing novel treatments to market. The company’s overarching mission is to alleviate patient suffering by continuously supporting drug development and fostering advancements in medical technology. SNBL aims to remain at the forefront of biomedical research, contributing to the health and well-being of people worldwide.